10-QPeriod: Q2 FY2024

AMGEN INC Quarterly Report for Q2 Ended Jun 30, 2024

Filed August 7, 2024For Securities:AMGN

Summary

Amgen Inc. reported a notable increase in total revenues for the second quarter of 2024, reaching $8.4 billion, a 20% rise compared to the same period in the prior year. This growth was primarily driven by a significant 20% increase in product sales, largely attributable to the successful integration of Horizon Therapeutics and strong volume growth across key products. Despite the top-line expansion, operating income and net income experienced a decline due to a substantial increase in operating expenses, primarily driven by higher amortization related to the Horizon acquisition and increased R&D and SG&A expenses. Diluted EPS saw a corresponding decrease. The company's balance sheet shows a decrease in cash and cash equivalents to $9.3 billion from $10.9 billion at the end of 2023, alongside a reduction in total assets and stockholders' equity. Long-term debt also decreased. Amgen continued its commitment to capital allocation through dividend payments, though no shares were repurchased during the first half of 2024. The company remains focused on investing in innovation and managing its debt.

Financial Highlights

53 data points
Beta

Revenue

$8.39B

61.4% Gross Margin

Net Income

$746.00M

8.9% Net Margin

EPS (Diluted)

$1.38

Total Assets

$90.91B

Cash & Equivalents

$9.30B

Free Cash Flow

$2.22B

Financial Statements
Beta
Revenue$8.39B
Cost of Revenue$3.24B
Gross Profit$5.15B
SG&A Expenses$1.78B
Operating Expenses$6.48B
Operating Income$1.91B
Interest Expense$808.00M
Net Income$746.00M
EPS (Basic)$1.39
EPS (Diluted)$1.38
Shares Outstanding (Basic)537.00M
Shares Outstanding (Diluted)541.00M

Key Highlights

  • 1Total revenues increased by 20% year-over-year to $8.4 billion for the second quarter of 2024, driven by a 20% increase in product sales.
  • 2Operating income decreased by 29% to $1.9 billion, and net income fell by 46% to $746 million, primarily due to a 51% increase in operating expenses.
  • 3Diluted Earnings Per Share (EPS) decreased by 46% to $1.38 for the quarter.
  • 4The acquisition of Horizon Therapeutics contributed significantly to product sales, with $1.1 billion in the current quarter.
  • 5Key products like Prolia, Repatha, TEZSPIRE, and the newly acquired TEPEZZA and KRYSTEXXA showed strong sales growth.
  • 6Cost of Sales as a percentage of product sales increased significantly to 40.2% from 27.1% in the prior year, largely due to amortization of acquisition-related assets.
  • 7Amgen maintained its dividend payments, declaring a quarterly cash dividend of $2.25 per share, but reported no share repurchases in the first half of 2024, with $7.0 billion authorization remaining.

Frequently Asked Questions

The primary driver for the substantial increase in operating expenses was higher amortization expense related to assets acquired from the Horizon Therapeutics acquisition, coupled with increased R&D and SG&A expenses associated with the expanded business and ongoing pipeline development.

While revenue grew significantly, a sharp increase in operating expenses, particularly amortization and R&D spend, outpaced revenue growth. This, combined with higher interest expenses, led to a substantial decrease in operating income and consequently, net income and EPS.

The Horizon acquisition significantly boosted product sales, contributing $1.1 billion in the current quarter from products like TEPEZZA and KRYSTEXXA. However, it also led to a substantial increase in operating expenses, notably higher amortization costs, which impacted profitability.

Amgen's capital allocation priorities include investing in innovation (internal and external), capital expenditures, debt repayment, dividends, and stock repurchases. The company has a solid cash position of $9.3 billion, though cash and cash equivalents decreased. They continue to prioritize shareholder returns through dividends, maintaining a quarterly payout of $2.25 per share, while no shares were repurchased in the first half of 2024.